Imlygic
These highlights do not include all the information needed to use IMLYGIC safely and effectively. See full prescribing information for IMLYGIC . I MLYGIC ( talimogene laherparepvec ) Suspension for intralesional injection Initial U.S. Approval: 2015
64ffb680-ea8c-42fc-9649-9e8c0eb77ddb
HUMAN PRESCRIPTION DRUG LABEL
Feb 10, 2023
Amgen Inc
DUNS: 039976196
Products 2
Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.
talimogene laherparepvec
Product Details
FDA regulatory identification and product classification information
FDA Identifiers
Product Classification
Product Specifications
INGREDIENTS (7)
talimogene laherparepvec
Product Details
FDA regulatory identification and product classification information